Report cards › Food › Aurora Products
AURORA
CSWH grade A (92)
Method v1.0 (how we grade), based on the records below; exact score 92.
| Indicator | Grade | What we found |
|---|---|---|
| Recalls (40%) | B (80) | 1 Class II (4 points) · 1 event For current recalls see FDA and USDA. |
| Ingredients (40%) | A (100) | Tier A: 0 of 16 products · A (100) (25%) Tier B: 0 of 16 products · A (100) (15%) |
| FDA warning letters (20%) | A (100) | None found to the owner Oct 28, 2021 to Oct 28, 2026. |
Shown, not graded: recall reasons (1 undeclared allergen) · IARC notes (0 products) · FDA dye pledge: none on FDA's tracker.
Recalls, Oct 28, 2021 to Oct 28, 2026
Class II, Sep 7, 2022 · Undeclared allergen · FDA event 90851
Aurora Natural brand; Organic Cranberry Frontier Mix UPC: 6 55852 00730 3; 19 oz (538g); Ingredients: ORGANIC DRIED CRANBERRIES (ORGANIC CANE SUGAR, ORGANIC SUNFLOWER OIL), ORGANIC RAISINS, ORGANIC DATES (ORGANIC OAT COVERING), ORGANIC CASHEWS, ORGANIC PEPITAS, ORGANIC ALMONDS. CONTAINS: CASHEWS, ALMONDS. May Contain: Peanuts, Other Tree Nuts, Milk, Soy, Wheat, Sesame; DISTRIBUTED BY AURORA PRODUCTS, INC. ORANGE, CT 06477; BEST IF USED BY 05/16/23
- Reason (FDA's words)
- Product contains undeclared peanuts.
- Code information
- BEST IF USED BY 05/16/23 UPC: 6 55852 00730 3
- Recalling firm
- Aurora Products, Inc.
- Dates
- Recall started Sep 7, 2022; classified Oct 4, 2022
- Status
- Terminated (status reported by FDA at classification)
- How we matched it
- matched by recalling firm (name) and brand name
FDA record F-0003-2023: openFDA · Report an error
Store-brand and co-packer recalls count on a brand only when a UPC in the recall matches one of its products.
Ingredients on our watch list
None of the 16 products with an ingredient statement contains a watched ingredient.
Labels change: each row shows the date of its FoodData Central record. A brand that has changed a recipe can report it with "Report an error".
FDA warning letters to Aurora Products, Oct 28, 2021 to Oct 28, 2026
None found from FDA food offices.
FDA notes that later events may have changed the regulatory status of what a letter discusses.